This clinical trial is focused on studying the effects of a medication called evolocumab on patients who have been hospitalized due to a heart attack, also known as an acute myocardial infarction. Heart attacks can occur when blood flow to the heart is blocked, often due to a buildup of cholesterol and other substances in the arteries. This study aims to see if adding evolocumab to the usual care for managing cholesterol levels can help reduce the risk of further heart-related problems, such as another heart attack, stroke, or the need for procedures to restore blood flow in the arteries.

Participants in the study will receive either evolocumab, which is also known by its code name AMG145, or a placebo, in addition to their regular cholesterol management. Evolocumab is given through an injection under the skin using a device called an autoinjector pen. The study will monitor participants over a period to observe any changes in their health, particularly focusing on the occurrence of heart attacks, strokes, and other cardiovascular events.

The purpose of this study is to determine if evolocumab, when used early during hospitalization for a heart attack, can effectively lower the risk of future cardiovascular events compared to standard cholesterol management alone. The study will also look at changes in cholesterol levels over time in a subset of participants. This research is important for understanding how to better protect heart health in patients who have experienced a heart attack.